Loading stock data…
LBRX
$31.43-0.28 (-0.88%)
After Hours$31.43+0.00 (+0.00%)· Last close May 1
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$31.43
Potential Upside
5%
Whystock Fair Value$33.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$911.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.37%
Volume
Today's trading volume
124,609
Recent News
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a “fully integrated company focused on CNS-related diseases,” Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia. Turner said the company’s lead program, LB-102, is a late
LB Pharmaceuticals Inc.: Q4 Earnings Snapshot
NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $11.5 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 45 cents.
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
LB Pharmaceuticals (NASDAQ:LBRX) CEO Heather Turner told investors the company is positioned for a series of “clinically meaningful value creating catalysts” following its most recent financing, with multiple late-stage readouts planned for its lead candidate LB-102 across several psychiatric indica
LB Pharmaceuticals initiates Phase 2 trial of LB-102
LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, “We believe LB-102’s ph
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $3.6 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 61 cents.